Adult Dosing
Contrast use in imaging (MRI)
- 0.1 mL/kg (0.1 mmol/kg) IV at a flow rate of 2 mL/second
Notes:- Administer as IV bolus, manually or using power injector
- Flush the IV cannula with physiological saline following injection
Pediatric Dosing
- Safety and effectiveness in pediatric patients <2 yrs have not been established
Contrast use in imaging (MRI)
- Children
2 yrs - 0.1 mL/kg (0.1 mmol/kg) IV at a flow rate of 2 mL/second
Notes:- Administer as IV bolus, manually or using power injector
- Flush the IV cannula with physiological saline following injection
[Outline]
See Supplemental Patient Information
- There is an increased risk of NSF associated with the use of GBCAs, in patients with impaired renal function. In such patients, use GBCAs only if the diagnostic information is essential and not available with non-contrasted MRI or other modalities [US Black Box Warning]
- In patients undergoing hemodialysis, initiate hemodialysis promptly following GBCA administration to increase its elimination
- Rare occurrences of anaphylactoid and anaphylactic reactions characterized by cardiovascular, respiratory or cutaneous conditions have been reported following gadobutrol administration
- Hypersensitivity reactions usually occur within half an hour following gadobutrol administration; however, delayed reactions may occur up to several days after administration. Monitor patients for such reactions during and after administration
- Ensure patency of the catheter and vein prior to administration. Moderate irritation may occur due to extravasation into tissues during administration. Do not administer via IM route
Cautions: Use cautiously in
Supplemental Patient Information
- Advise patients to promptly seek medical attention if they develop signs or symptoms of NSF following agent administration including itching, burning, swelling, scaling, hardening and tightening of the skin; red or dark patches on the skin; muscle weakness; stiffness in joints with trouble moving, bending or straightening the arms, hands, legs or feet; or pain in the ribs or hip bones
- Instruct patients to inform their physician if they are pregnant or breastfeeding, taking any prescription medications, or have a history of allergic reaction to contrast media, bronchial asthma or allergic respiratory disorder
Pregnancy Category:C
Breastfeeding: Safety unknown. Non-clinical data and limited clinical data suggest that gadobutrol is minimally excreted in human milk and its absorption via GI tract is poor. Manufacturer advises caution when administering to a nursing woman.
